177 related articles for article (PubMed ID: 37612635)
21. Impact of Neoadjuvant Therapy in Resected Pancreatic Ductal Adenocarcinoma of the Pancreatic Body or Tail on Surgical and Oncological Outcome: A Propensity-Score Matched Multicenter Study.
Lof S; Korrel M; van Hilst J; Alseidi A; Balzano G; Boggi U; Butturini G; Casadei R; Dokmak S; Edwin B; Falconi M; Keck T; Malleo G; de Pastena M; Tomazic A; Wilmink H; Zerbi A; Besselink MG; Abu Hilal M;
Ann Surg Oncol; 2020 Jun; 27(6):1986-1996. PubMed ID: 31848815
[TBL] [Abstract][Full Text] [Related]
22. IPMN-associated pancreatic cancer: Survival, prognostic staging and impact of adjuvant chemotherapy.
Kaiser J; Scheifele C; Hinz U; Leonhardt CS; Hank T; Koenig AK; Tjaden C; Hackert T; Bergmann F; Büchler MW; Strobel O
Eur J Surg Oncol; 2022 Jun; 48(6):1309-1320. PubMed ID: 34920899
[TBL] [Abstract][Full Text] [Related]
23. Proposal of a modified American Joint Committee on Cancer staging scheme for resectable pancreatic ductal adenocarcinoma with a lymph node ratio-based N classification: A retrospective cohort study.
Li HJ; Chen YT; Yuan SQ
Medicine (Baltimore); 2018 Aug; 97(34):e12094. PubMed ID: 30142869
[TBL] [Abstract][Full Text] [Related]
24. Validation of the American Joint Committee on Cancer 8th edition staging system for the pancreatic ductal adenocarcinoma.
Shin DW; Lee JC; Kim J; Woo SM; Lee WJ; Han SS; Park SJ; Choi KS; Cha HS; Yoon YS; Han HS; Hong EK; Hwang JH
Eur J Surg Oncol; 2019 Nov; 45(11):2159-2165. PubMed ID: 31202572
[TBL] [Abstract][Full Text] [Related]
25. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
[TBL] [Abstract][Full Text] [Related]
26. Comparative Effectiveness of Neoadjuvant Therapy and Upfront Resection for Patients with Resectable Pancreatic Adenocarcinoma: An Instrumental Variable Analysis.
da Costa WL; Tran Cao HS; Sheetz KH; Gu X; Norton EC; Massarweh NN
Ann Surg Oncol; 2021 Jun; 28(6):3186-3195. PubMed ID: 33174146
[TBL] [Abstract][Full Text] [Related]
27. Neoadjuvant Therapy Versus Upfront Resection for Pancreatic Cancer: The Actual Spectrum and Clinical Burden of Postoperative Complications.
Marchegiani G; Andrianello S; Nessi C; Sandini M; Maggino L; Malleo G; Paiella S; Polati E; Bassi C; Salvia R
Ann Surg Oncol; 2018 Mar; 25(3):626-637. PubMed ID: 29214453
[TBL] [Abstract][Full Text] [Related]
28. Accuracy of models to prognosticate survival after surgery for pancreatic cancer in the era of neoadjuvant therapy.
Marcinak CT; Parker WF; Parikh AA; Datta J; Maithel SK; Kooby DA; Burkard ME; Kim HJ; LeCompte MT; Afshar M; Churpek MM; Zafar SN
J Surg Oncol; 2023 Aug; 128(2):280-288. PubMed ID: 37073788
[TBL] [Abstract][Full Text] [Related]
29. GRP78 expression and prognostic significance in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant therapy versus surgery first.
Tong YT; Wang H; Wei D; Prakash LR; Kim M; Tzeng CD; Lee JE; Rashid A; Koay EJ; Wolff RA; Maitra A; Katz MH; Wang H
Pancreatology; 2021 Oct; 21(7):1378-1385. PubMed ID: 34429247
[TBL] [Abstract][Full Text] [Related]
30. Integrated Pathologic Score Effectively Stratifies Patients With Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant Therapy and Pancreaticoduodenectomy.
Sohn AJ; Taherian M; Katz MHG; Prakash LR; Chatterjee D; Wang H; Kim M; Tzeng CD; Lee JE; Ikoma N; Rashid A; Wolff RA; Zhao D; Koay EJ; Sun R; Maitra A; Wang H
Am J Surg Pathol; 2023 Apr; 47(4):421-430. PubMed ID: 36746143
[TBL] [Abstract][Full Text] [Related]
31. Can a simplified CT response criteria for vascular involvement in pancreatic adenocarcinoma after neoadjuvant therapy predict survival in patients who achieved subsequent R0 resection?
Guo Y; Czeyda-Pommersheim F; Miccio JA; Mahalingam S; Cecchini M; Pahade J
Abdom Radiol (NY); 2021 Dec; 46(12):5609-5617. PubMed ID: 34557934
[TBL] [Abstract][Full Text] [Related]
32. Survival impact of neoadjuvant therapy in resected pancreatic cancer: A Prospective Cohort Study involving 18,332 patients from the National Cancer Data Base.
Mirkin KA; Hollenbeak CS; Wong J
Int J Surg; 2016 Oct; 34():96-102. PubMed ID: 27573691
[TBL] [Abstract][Full Text] [Related]
33. Validation and modification of the AJCC 8th TNM staging system for pancreatic ductal adenocarcinoma in a Chinese cohort: A nationwide pancreas data center analysis.
Hu H; Qu C; Tang B; Liu W; Ma Y; Chen Y; Xie X; Zhuang Y; Gao H; Tian X; Yang Y
Chin J Cancer Res; 2021 Aug; 33(4):457-469. PubMed ID: 34584371
[TBL] [Abstract][Full Text] [Related]
34. Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Treatment Does Not Predict Pathological Response and Survival in Resectable Pancreatic Ductal Adenocarcinoma.
Strong JS; Vos EL; Mcintyre CA; Chou JF; Gonen M; Tang LH; Soares KC; Balachandran VP; Kingham TP; D'Angelica MI; Jarnagin WR; Drebin J; Kunstman JW; Allen PJ; Wei AC
Am Surg; 2022 Jun; 88(6):1153-1158. PubMed ID: 33517697
[TBL] [Abstract][Full Text] [Related]
35. The number and ratio of positive lymph nodes affect pancreatic cancer patient survival after neoadjuvant therapy and pancreaticoduodenectomy.
Fischer LK; Katz MH; Lee SM; Liu L; Wang H; Varadhachary GR; Wolff RA; Lee JE; Maitra A; Roland CL; Fleming JB; Estrella J; Rashid A; Wang H
Histopathology; 2016 Jan; 68(2):210-20. PubMed ID: 25945396
[TBL] [Abstract][Full Text] [Related]
36. The diversity between curatively resected pancreatic head and body-tail cancers based on the 8th edition of AJCC staging system: a multicenter cohort study.
Sheng W; Dong M; Wang G; Shi X; Gao W; Wang K; Song H; Shi G; Tan X
BMC Cancer; 2019 Oct; 19(1):981. PubMed ID: 31640615
[TBL] [Abstract][Full Text] [Related]
37. Impact of Neoadjuvant Therapy on Survival Following Margin-Positive Resection for Pancreatic Cancer.
Chopra A; Zenati M; Hogg ME; Zeh HJ; Bartlett DL; Bahary N; Zureikat AH; Beane JD
Ann Surg Oncol; 2021 Nov; 28(12):7759-7769. PubMed ID: 34027585
[TBL] [Abstract][Full Text] [Related]
38. Does Site Matter? Impact of Tumor Location on Pathologic Characteristics, Recurrence, and Survival of Resected Pancreatic Ductal Adenocarcinoma.
Malleo G; Maggino L; Ferrone CR; Marchegiani G; Luchini C; Mino-Kenudson M; Paiella S; Qadan M; Scarpa A; Lillemoe KD; Bassi C; Fernàndez-Del Castillo C; Salvia R
Ann Surg Oncol; 2020 Oct; 27(10):3898-3912. PubMed ID: 32307617
[TBL] [Abstract][Full Text] [Related]
39. Optimized modification of the eighth edition of AJCC TNM staging system for resected pancreatic ductal adenocarcinoma.
Pu N; Yin L; Habib JR; Gao S; Hu H; Zhu Y; Wu Y; Yu J; Lou W
Future Oncol; 2019 Oct; 15(30):3457-3465. PubMed ID: 31460788
[No Abstract] [Full Text] [Related]
40. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
